MNG1173
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.350
- ANDROGEN_RESPONSE+0.320
- TGF_BETA_SIGNALING+0.287
- UV_RESPONSE_DN+0.183
- SPERMATOGENESIS+0.120
- ESTROGEN_RESPONSE_EARLY+0.111
- PANCREAS_BETA_CELLS+0.089
- KRAS_SIGNALING_UP+0.085
- ESTROGEN_RESPONSE_LATE+0.083
- HEME_METABOLISM+0.046
Top 10 suppressed
- MYC_TARGETS_V2-0.481
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- ANGIOGENESIS-0.322
- ALLOGRAFT_REJECTION-0.319
- UV_RESPONSE_UP-0.287
- MYOGENESIS-0.282
- IL6_JAK_STAT3_SIGNALING-0.281
- UNFOLDED_PROTEIN_RESPONSE-0.271
- INTERFERON_ALPHA_RESPONSE-0.245
- CHOLESTEROL_HOMEOSTASIS-0.234
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A1F5-01A-12R-A13Q-07 | — | B | 0.857 |
| 2 | MNG636 | — | — | 0.798 |
| 3 | R141 | — | — | 0.793 |
| 4 | TCGA-A7-A26E-01A-11R-A169-07 | — | B | 0.789 |
| 5 | TCGA-A7-A13G-01A-11R-A13Q-07 | — | D | 0.783 |
| 6 | SJEPD030399_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.778 |
| 7 | 84a15687-a977-43a1-b2b7-099ecdf21b2c | — | — | 0.766 |
| 8 | R347 | — | — | 0.766 |
| 9 | SRR6013519 | — | cohortA1 | 0.757 |
| 10 | TCGA-A7-A26E-01A-11R-A277-07 | — | D | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.287 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.183 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.111 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.089 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.085 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.083 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.046 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.037 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.034 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.033 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.007 | Inavolisib | — uncovered |
| PEROXISOME | 0.001 | Idelalisib | — uncovered |